Yesterday, Dec. 16, 2015, 113 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $10.88 to $18,402,925.00.

Highlighted Stocks Traded by Insiders:

Shoe Carnival (SCVL) - FREE Research Report

Scibetta Carl N., who is Evp - General Merchandise Mgr at Shoe Carnival, sold 2,865 shares at $23.00 on Dec. 16, 2015. Following this transaction, the Evp - General Merchandise Mgr owned 47,963 shares meaning that the stake was reduced by 5.64% with the 2,865-share transaction.

The shares most recently traded at $23.08, up $0.08, or 0.35% since the insider transaction. Historical insider transactions for Shoe Carnival go as follows:

  • 4-Week # shares sold: 5,000
  • 12-Week # shares sold: 5,000
  • 24-Week # shares sold: 5,000

The average volume for Shoe Carnival has been 123,400 shares per day over the past 30 days. Shoe Carnival has a market cap of $456.7 million and is part of the services sector and retail industry. Shares are down 9.15% year-to-date as of the close of trading on Wednesday.

Shoe Carnival, Inc. operates as a family footwear retailer in the United States. It provides various dress, casual, and athletic footwear products for men, women, and children; and accessories, such as handbags, shoe care items, and socks. The stock currently has a dividend yield of 1.14%. The company has a P/E ratio of 16.6. Currently, there is 1 analyst who rates Shoe Carnival a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SCVL - FREE

TheStreet Quant Ratings rates Shoe Carnival as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, attractive valuation levels and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, a generally disappointing performance in the stock itself and poor profit margins. Get the full Shoe Carnival Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Zogenix (ZGNX) - FREE Research Report

Hawley Roger, who is Director at Zogenix, bought 10,000 shares at $13.74 on Dec. 16, 2015. Following this transaction, the Director owned 1.4 million shares meaning that the stake was boosted by 0.72% with the 10,000-share transaction.

The shares most recently traded at $13.71, down $0.03, or 0.24% since the insider transaction. Historical insider transactions for Zogenix go as follows:

  • 4-Week # shares bought: 5,000
  • 4-Week # shares sold: 84,436
  • 12-Week # shares bought: 5,000
  • 12-Week # shares sold: 84,436
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 84,436

The average volume for Zogenix has been 391,800 shares per day over the past 30 days. Zogenix has a market cap of $338.0 million and is part of the health care sector and drugs industry. Shares are up 22.17% year-to-date as of the close of trading on Friday.

Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States. Its marketed product includes Zohydro ER, an extended-release formulation of hydrocodone for the treatment of severe chronic pain. Currently, there are 4 analysts who rate Zogenix a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on ZGNX - FREE

TheStreet Quant Ratings rates Zogenix as a sell. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, disappointing return on equity, poor profit margins and feeble growth in its earnings per share. Get the full Zogenix Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

First Merchants (FRME) - FREE Research Report

Becher Michael R, who is Director at First Merchants, bought 150 shares at $25.36 on Dec. 16, 2015. Following this transaction, the Director owned 6,860 shares meaning that the stake was boosted by 2.24% with the 150-share transaction.

The shares most recently traded at $25.93, up $0.57, or 2.2% since the insider transaction. Historical insider transactions for First Merchants go as follows:

  • 4-Week # shares bought: 79
  • 4-Week # shares sold: 1,600
  • 12-Week # shares bought: 306
  • 12-Week # shares sold: 1,600
  • 24-Week # shares bought: 573
  • 24-Week # shares sold: 1,600

The average volume for First Merchants has been 127,800 shares per day over the past 30 days. First Merchants has a market cap of $981.7 million and is part of the financial sector and banking industry. Shares are up 14.46% year-to-date as of the close of trading on Wednesday.

First Merchants Corporation operates as the financial holding company for First Merchants Bank, National Association that provides community banking services. The stock currently has a dividend yield of 1.7%. The company has a P/E ratio of 14.7. Currently, there is 1 analyst who rates First Merchants a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on FRME - FREE

TheStreet Quant Ratings rates First Merchants as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income, expanding profit margins, solid stock price performance and notable return on equity. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full First Merchants Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.